Sign in to fuzzto save your conversations, follow your research and come back anytime.
Ajanta Pharma
AJANTPHARM
NSE
BSE
NSEBSESectorHealthcare
3,521.10
Loading chart…
About the company
Ajanta Pharma is an Indian specialty pharmaceutical company focusing on branded generic products. It operates in India, Asia, Africa, and the USA, offering a range of therapeutic products including cardiology, dermatology, ophthalmology, and pain management. The company has seven manufacturing facilities in India and Mauritius, with two approved by the US FDA. Ajanta Pharma has a strong research and development center in Mumbai with over 750 scientists. The company's business includes branded generics in emerging markets, generics in the USA, and institutional sales. Established in 1973, Ajanta Pharma has expanded its operations over the years, entering new markets and launching various products. The company is publicly listed on the BSE and NSE, and has undertaken several expansion projects and buybacks in recent years.
In the news
Ajanta Pharma Stock Falls 2.06% to ₹3365.60 Despite Strong Q1 Results
Ajanta Pharma Q1 profit jumps 31% on strong US sales, Prabhudas targets ₹3730
Ajanta Pharma gets USFDA EIR for Paithan facility with VAI status
Ajanta Pharma promoter sells ₹1,024 cr stake amid midcap fund selling
BlueStone Jewellery shares fall 6.5% on ₹300 crore block deal
Titan shares surge 2% on JP Morgan 'overweight' rating; Q4 profit jumps 35%
Ajanta Pharma's Paithan plant gets 5 USFDA observations
Ajanta Pharma, Sun Pharma eye GLP-1 market opportunity
Zydus-Lupin partner for semaglutide co-marketing ahead of patent expiry
Tech stocks face correction as Iran escalates Strait of Hormuz conflict
Ajanta Pharma posts 17.6% Q3 profit growth on 20% revenue rise